May 30, 2026 Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 30, 2026 Prostate Health Supplements From PureHealth Research Enhance Bladder Control With Clinical Lycopene
